1	Effectiveness of BNT162b2 and ChAdOx1 vaccines against symptomatic COVID-19 among
2	Healthcare Workers in Kuwait: A retrospective cohort study
3	Walid Q. Alali <sup>1*</sup> , Lamiaa A. Ali <sup>2</sup> , Mohammad AlSeaidan <sup>3</sup> , Mohammad Al-Rashidi <sup>4</sup>
4	<sup>1</sup> Department of Epidemiology & Biostatistics, Faculty of Public Health, Kuwait University,
5	Safat, Kuwait
6	<sup>2</sup> Quality and accreditation directorate, Farwania Hospital, Farwania, Kuwait
7	<sup>3</sup> Department of Public Health, Ministry of Health, Kuwait City, Kuwait
8	<sup>4</sup> Hospital Administration, Farwania Hospital, Farwania, Kuwait
9	
10	
11	*Corresponding author:
12	Walid Q. Alali
13	Department of Epidemiology and Biostatistics
14	Faculty of Public Health
15	Kuwait University
16	Safat, Kuwait
17	

17 <u>w.alali@ku.edu.kw</u>

#### Abstract

19 Background: The COVID-19 BNT162b2 vaccination roll-out in Kuwait started on 24 December 20 2020 followed by ChAdOx1 on 3 February 2021. The study objectives were to assess the factors 21 associated with vaccine coverage and determine vaccine effectiveness (VE) against SARS-CoV-22 2 infection in a healthcare worker (HCW) population. 23 **Methods**: This retrospective cohort study was conducted among HCW working at a public 24 secondary hospital in Kuwait. The follow-up period was from 24 December 2020 to 15 June 25 2021. The primary outcomes were vaccine coverage and PCR-confirmed SARS-CoV-2 infection 26 for the VE analysis. Data on new SARS-CoV-2 infections (with or without symptoms) during 27 study period in addition to HCWs characteristics (sex, age, nationality, and occupation) were 28 extracted from the hospital records. The vaccine coverage and PCR-confirmed SARS-CoV-2 29 infections were cross-tabulated by the HCWs characteristics. Furthermore, we used Cox 30 regression to estimate time-to-infection hazard ratios in vaccinated (first and second dose) 31 compared to unvaccinated HCWs. Only one ChAdOx1 dose was given during the study period. 32 **Results:** There were 3246 HCWs included in the analysis. The median age was 38 years (IQR = 33 33 - 44), 63.4% were females, 46.8% aged 31-40, and 82.3% were non-Kuwaitis. Overall, 82.1% 34 of HCWs received at least one vaccine dose (50.4% received only one dose of ChAdOx1, 3.3% 35 received one dose of BNT162b2, and 28.3% received two doses of BNT162b2). 17.9% of HCWs 36 remained unvaccinated by the end of the study. A significantly lower vaccination coverage 37 percentage was amongst female HCWs, younger age group (20 - 30 years old), and 38 administrative/executive staff. Symptomatic SARS-CoV-2 PCR-confirmed infection prevalence was 7.3%. No asymptomatic infections were reported. The SARS-CoV-2 infection incidence rate 39 40 was 126 per 100,000 person-days in the unvaccinated group; whereas, the incidence rates in the

- 41 partially vaccinated groups ( $\geq$  28 days after ChAdOx1 first dose) and ( $\geq$  14 days after receiving
- 42 BNT162b2 through receipt of second dose) were 31.4 and 10.9 per 100,000 person-days,
- 43 respectively. In the fully vaccinated group ( $\geq$  14 days after BNT162b2 second dose), the
- 44 incidence rate was 6.3 per 100,000 person-days. The estimated adjusted vaccine effectiveness of
- 45 fully vaccinated was 94.5% (95% confidence interval [CI] = 89.4%–97.2%). The VE of partially
- 46 vaccinated for ChAdOx1 and BNT162b2 was 75.4% (95% CI = 67.2%-81.6%) and 91.4% (95%
- 47 CI = 65.1% 97.9%), respectively.
- 48 Conclusions: Both BNT162b2 and ChAdOx1 vaccines prevented most symptomatic infections
- 49 in this population across age groups, nationalities, and occupations. A significant proportion
- 50 (17.9%) of HCWs were unvaccinated despite the vaccine accessibility. The findings complement
- 51 other VE studies and demonstrate the vaccine benefit among HCWs.

# 53 **1. Introduction**

54	The two anti-COVID-19 vaccines (BNT162b2 mRNA [Pfizer-BioNTech] and ChAdOx1
55	nCoV-19 adenoviral [Oxford-AstraZeneca] have shown to be effective in preventing
56	asymptomatic/symptomatic COVID-19, hospitalization, and death based on both clinical trials
57	and population-level observational studies (Abu-Raddad, Chemaitelly, & Butt, 2021; Haas et al.,
58	2021; Hall et al., 2021; Polack et al., 2020; Vasileiou et al., 2021; Voysey et al., 2021). Both
59	vaccines have been authorized for use in Kuwait. Local BNT162b2 vaccination roll-out started
60	on 24 <sup>th</sup> December 2020 followed by ChAdOx1 on 3 <sup>rd</sup> February 2021.
61	COVID-19 vaccine effectiveness under 'real-world' conditions are important to conduct not
62	only in the general population but also in risk-specific groups such as healthcare workers
63	(HCWs) due to their higher exposure rates to SARS-CoV-2. It is well-known that HCWs come
64	in contact with patients directly and indirectly depending on their occupation. Therefore, they
65	considered high risk group for SARS-CoV-2 infection and consequently at risk for disease
66	complications. Recent studies have shown that vaccination reduce the rate of infection among
67	HCWs (Amit, Regev-Yochay, Afek, Kreiss, & Leshem, 2021; Hall et al., 2021; Moustsen-Helms
68	et al., 2021; Thompson et al., 2021). In the study from Israel, the incidence rate among
69	BNT162b2 vaccinated HCWs was 3 cases per 10,000 person-days compared to 7.4 cases per
70	10,000 person-day in unvaccinated (Amit et al., 2021). Moreover, a study from United Kingdom
71	(UK) revealed that in a single dose of BNT162b2 vaccine was 70% effective in reducing SARS-
72	CoV-2 infections among HCWs 21 days after first dose and 85% after 7 days post second dose
73	(Hall et al., 2021). Furthermore, a study from United States (US) on two mRNA vaccines
74	(BNT162b2 and Moderna mRNA-1273) among HCWs, full immunization (≥14 days after
75	second dose) was 90% effective against SARS-CoV-2 infections regardless of the symptom's

status and 80% effectiveness in partially immunized (≥14 days after first dose but before second
dose).

78	While there are few studies that mostly evaluated impact of mRNA vaccines effectiveness in
79	HCWs population; there is limited data on mRNA and non-mRNA vaccine effectiveness in
80	HCWs population. Furthermore, there has been no published study on vaccine effectiveness
81	among HCWs in Gulf Cooperation Council countries and most of Middle Eastern countries.
82	Therefore, the objective of this retrospective cohort study was to assess the two vaccines
83	(BNT162b2 and ChAdOx1) effectiveness against symptomatic SARS-CoV-2 infection and in
84	relation to healthcare workers characteristics. We anticipate that the study findings will inform
85	HCWs across the country, the region, and internationally of the importance of vaccination
86	against COVID-19.
07	2. Methods
87	2. Methous
87 88	<ol> <li>2.1. Study design and study population</li> </ol>
88	2.1. Study design and study population
88 89	<ul><li>2.1. Study design and study population</li><li>The study was a retrospective cohort study among HCWs working at a public secondary</li></ul>
88 89 90	2.1. Study design and study population The study was a retrospective cohort study among HCWs working at a public secondary hospital in Kuwait. The hospital is a 900-bed facility with multiple medical and surgical
88 89 90 91	2.1. Study design and study population The study was a retrospective cohort study among HCWs working at a public secondary hospital in Kuwait. The hospital is a 900-bed facility with multiple medical and surgical specialties including outpatient polyclinics. The original study population was 3673 HCWs (aged
88 89 90 91 92	2.1. Study design and study population The study was a retrospective cohort study among HCWs working at a public secondary hospital in Kuwait. The hospital is a 900-bed facility with multiple medical and surgical specialties including outpatient polyclinics. The original study population was 3673 HCWs (aged ≥ 20 years) working at this hospital. The study started on 24 <sup>th</sup> December 2020 (i.e., the day
88 89 90 91 92 93	2.1. Study design and study population The study was a retrospective cohort study among HCWs working at a public secondary hospital in Kuwait. The hospital is a 900-bed facility with multiple medical and surgical specialties including outpatient polyclinics. The original study population was 3673 HCWs (aged ≥ 20 years) working at this hospital. The study started on 24 <sup>th</sup> December 2020 (i.e., the day vaccine roll-out began in Kuwait). HCWs with PCR-confirmed SARS-CoV-2 before the start of

96 CoV-2 PCR-confirmed infections.

97 The study was approved by the Ministry of Health Standing Committee for the
98 Coordination of Health and Medical Research (i.e., Ethics Committee), Kuwait City, Kuwait
99 (Approval number: 1666/2021).

100 **2.2. Data collection** 

101 Vaccination data were obtained from the hospital records. The hospital administration staff started collecting vaccination data on 10<sup>th</sup> January 2021 from all HCWs. They regularly 102 103 followed up with all hospital departments and requested specific vaccine-related data on HCWs 104 including vaccination status (vaccinated or unvaccinated); vaccination date (for first and second 105 dose); vaccine type (BNT162b2 or ChAdOx1); SARS-CoV-2 PCR-confirmed infections 106 (symptomatic or asymptomatic) and infection date. Additionally, sociodemographic (sex, age, 107 and nationality), occupation setting (e.g., outpatient, inpatient, intensive care), and staff 108 occupation (e.g., doctor, nurse, pharmacist) were available in the hospital records. The 109 sociodemographic and occupation data were matched with collected vaccination data using the 110 civil identification number of the HCWs. The HCW testing for SARS-CoV-2 was voluntary on 111 the basis of appearance of COVID-19 like symptoms or being a close-contact with COVID-19 112 positive case. A HCW was considered COVID-19 symptomatic if he/she had at least one typical 113 disease symptoms such as fever, cough, or change in taste or smell. However, the vaccination 114 records did not specify the range of symptoms but rather classified the infection as either 115 symptomatic or asymptomatic.

The full data were extracted from the hospital records on 15<sup>th</sup> June 2021. To avoid
misclassification of exposure, HCWs with missing vaccination information (e.g., no vaccination
date or vaccination type) or missing PCR testing information were excluded from the study.
Furthermore, the analysis excluded 24 HCWs who had a documented SARS-CoV-2 PCR-

120 confirmed infection prior to the study's starting date and additional 403 HCWs who had missing
121 or incomplete vaccination data or symptom data were also excluded. Hence, a total of 3246
122 HCWs eligible for this study.

123 **2.3.** Outcomes

124 The primary outcome for vaccine effectiveness analysis was the SARS-CoV-2 PCR-

125 confirmed infection among unvaccinated or vaccinated at any time during the study (i.e., during

126 the follow-up time) irrespective of symptom status. Infections were described as symptomatic if

127 their symptom status was seven days before or seven days of their PCR positive test date.

128 The primary outcome for the vaccine coverage analysis was the vaccination status (first 129 or second dose) by vaccine type. Healthcare workers vaccinated with ChAdOx1 had received 130 only one dose by the end of study period. This was due to the delay in ChAdOx1 vaccine 131 shipment to Kuwait that resulted in unavailability of the second dose for some HCWs who were 132 vaccinated in February and March (12-week waiting period between two doses). The ChAdOx1 133 shipment arrived to Kuwait on 13<sup>th</sup> June 2021; however, none of HCWs in this study received 134 the second dose by 15<sup>th</sup> June 2021.

135 **2.4.** Person-time at risk

The follow-up of all HCWs started on 24 December 2020, the day vaccine roll-out started in Kuwait. All HCWs had at least one day of follow-up as unvaccinated. For each HCW, the follow-up time (person-time at risk) ended at the earliest of the following events: occurrence of an outcome event (SARS-CoV-2 PCR-confirmed infection), vaccination (for unvaccinated), or end of study period.

141 **2.5.** Data analysis

142	Data were stratified by sociodemographic and occupation factors (i.e., covariates). These
143	were: age group (20 -30, 31- 40, $41 - 50$ , and >50), sex (male or female), nationality (Kuwaiti
144	national and non-Kuwaiti resident), staff group (Administrative or Executive; Nursing or Health-
145	care assistant; Doctor; Specialist Staff; Estates, Porters, or Security; and Pharmacist) and
146	occupation settings (categorized into six groups: 1) office or laboratory, 2) hospital pharmacy, 3)
147	outpatient including radiology, day ward, general practice, or renal dialysis unit, 4) inpatient
148	ward, theatres, emergency department, maternity unit or labor ward, or ambulance, 5) intensive
149	care, and 6) other (e.g., plaster and observational rooms).
150	For vaccine coverage analysis, we cross-tabulated three vaccination statuses as
151	unvaccinated; vaccinated with one ChAdOx1 dose; and vaccinated with one or two doses of
152	BNT162b2 with the study covariates. The relationship between vaccine coverage status and
153	covariates were assessed via chi-square statistic using STATA software version 16.1 (College
154	Station, Texas, USA). Furthermore, we also cross-tabulated SARS-CoV-2 PCR-confirmed
155	infection by vaccination status and each level of the covariates. Similarly, chi-square statistic
156	was used to assess relationships.
157	We used retrospective cohort study design to estimate the vaccine effectiveness in HCWs
158	population after the first and second dose. For the purpose of vaccine effectiveness analysis, the
159	HCWs were defined as unvaccinated (if they had not received any doses of either vaccine), fully
1.00	

160 vaccinated (if at least 14 days had passed since receiving the second dose of BNT162b2), and

161 partial vaccination (if at least 28 days passed since receiving ChAdOx1 first dose or at least 14

162 days after receiving BNT162b2 first dose but before receiving second dose). The BNT162b2 13

163 person-days between receiving vaccine first dose and partial or full vaccination were considered

164 excluded from the analysis as at-risk person-time because immunity was considered

165	indeterminate. Similarly, the ChAdOx1 27 person-days after receiving vaccine first dose were
166	excluded. Therefore, incidence rates were calculated for: unvaccinated, $\geq 28$ days after receiving
167	ChAdOx1 first dose, $\geq$ 14 days after receiving BNT162b2 first dose through receipt of second
168	dose, and $\geq$ 14 days after BNT162b2 second dose. Hazard ratios were estimated using Cox
169	proportional hazards model while accounting for time-varying vaccination status (i.e., receiving
170	first and second dose) as described elsewhere (Zhang, Reinikainen, Adeleke, Pieterse, &
171	Groothuis-Oudshoorn, 2018). Hazard ratios of partial vaccination person-days (≥ 28 days after
172	receiving ChAdOx1 first dose; ≥14 days after receiving BNT162b2 first dose and before second
173	dose) and to full vaccination person-days (≥14 days after BNT162b2 second dose) were
174	calculated and compared to that in unvaccinated person-days. Vaccine effectiveness was
175	calculated as 100% × (1–hazard ratio). An adjusted vaccine effectiveness model included the
176	covariates individually (i.e., univariate models) and those were significant at $P < 0.1$ were
177	included the multivariate model. All analyses were conducted in STATA statistical software.
178	

#### 179 **3. Results**

There were 3246 HCWs that met the inclusion criteria and included in the analysis. The median age of HCWs was 38 years (IQR = 33 - 44). Most of HCWs were females (63.4%), aged 31-40 (46.8%), non-Kuwaiti (82.3%), and worked in inpatient wards or ambulance settings (47.3%) as shown in Table 1. Furthermore, 61.2% of HCWs were nursing or health-care assistant staff.

Overall, 82.1% of HCWs received at least one vaccine dose while 17.9% of HCWs
remained unvaccinated by the end of the study. Interestingly, about half of the HCWs (50.4%)
received only one dose of ChAdOx1 vaccine; whereas 3.3% received one dose of BNT162b2

188	vaccine and 28.3% received two doses of BNT162b2 vaccine. Those who received only one dose
189	of BNT162b2 (3.3%) did not received their second dose because they were SARS-CoV-2
190	infected after the first dose (only two HCWs) or the study ended before they received it.
191	The percentage of HCWs classified as partially vaccinated (i.e., $\geq 28$ days after receiving
192	one dose of ChAdOx1 or $\geq$ 14 days after receiving BNT162b2 first dose through receipt of
193	second dose) was 50.2% and 2.8%, respectively. However, the percentage of HCWs classified
194	as fully vaccinated ( $\geq$ 14 days after BNT162b2 second dose) was 28.2%.
195	The characteristics of unvaccinated and vaccinated HCWs by the two types of vaccine
196	are shown in Table 1. Twenty percent of females were unvaccinated compared to 10.6% of
197	males (P <0.001). For age groups, 28.2% of HCWs aged 20-30 were unvaccinated, significantly
198	higher than other age groups (P $< 0.001$ ); whereas, within those received one or two doses of
199	BNT162b2 vaccine, the percentage of vaccinated HCWs in age groups $(20 - 30 \text{ and } > 50)$ was
200	higher than that in other age groups (P $< 0.001$ ). Interestingly, the percentages of unvaccinated
201	Kuwaitis (20.7%) and non-Kuwaitis (17.3%) HCWs were not significantly different ( $P = 0.054$ );
202	however, within those received one or two doses of BNT162b2, 60.7% of Kuwaiti HCWs were
203	vaccinated compared to 25.8% for non-Kuwaitis (P < 0.001). Among the different occupation
204	settings, 23.3% of HCWs who worked in office or laboratories were unvaccinated, significantly
205	higher compared to the remaining settings (P < $0.001$ ) except for 'other'. As for the HCW staff
206	groups, 31.5% of administrative or executive staff were unvaccinated, significantly higher than
207	other groups (P <0.001). In addition, 58.4% of doctors received one or two doses of BNT162b2
208	vaccine significantly higher than other staff groups (P < 0.001).

210	SARS-CoV-2 PCR-confirmed infection prevalence with reported symptoms was 7.3%
211	(237/3246) during the study period. There were two additional SARS-CoV-2 PCR-confirmed
212	HCW infections with missing symptomatic status; hence, they were excluded from the analysis.
213	Therefore, all the 237 SARS-CoV-2 PCR-confirmed infection were classified as symptomatic.
214	As shown in Table 2, the infection prevalence was significantly higher among unvaccinated
215	female HCWs (20.8%) compared to 7.1% in those vaccinated with ChAdOx1 and 1.96% in those
216	vaccinated with one or two doses of BNT162b2. Similar findings were observed among male
217	HCWs. SARS-CoV-2 PCR-confirmed prevalence in the different age-groups and by nationality
218	were significantly higher in unvaccinated compared to the vaccinated groups. Furthermore, the
219	infection prevalence was significantly higher across the unvaccinated occupation settings
220	compared to those in vaccinated occupation settings except for "other" where the differences
221	were not significant ( $P = 0.508$ ). The infection prevalence in staff groups were also significantly
222	higher in unvaccinated compared to vaccinated except for pharmacists ( $P = 0.866$ ) (Table 2).
223	
224	There were 114 SARS-CoV-2 infection during the 90,484 person-days of follow-up in
225	the unvaccinated group, an incidence rate of 126 per 100,000 person-days (Table 3). In the
226	partially vaccinated group, $\geq 28$ days after ChAdOx1 first dose, there were 87 infections
227	(incidence rate of 31.4 per 100,000 person-days). Moreover, in the partially vaccinated group ( $\geq$
228	14 days after receiving BNT162b2 vaccine through receipt of second dose), there were two
229	infections (incidence rate of 10.9 per 100,000 person-days). In the fully vaccinated group ( $\geq 14$
230	days after BNT162b2 second dose) there were 10 infections (incidence rate of 6.3 per 100,000

232

231

person-days).

233	The estimated adjusted vaccine effectiveness of fully vaccinated was 94.5% (95%
234	confidence interval [CI] = 89.4%–97.2%). The vaccine effectiveness of partially vaccinated for
235	ChAdOx1 ( $\geq$ 28 days after one dose) was 75.4% (95% CI = 67.2%–81.6%) and for one dose
236	BNT162b2 (≥ 14 days through receipt of second dose) was 91.4% (95% CI = 65.1%–97.9%)
237	(Table 3). The individual covariates (sex, age group, nationality, occupation setting, staff group)
238	were significant predictors; hence, included in the multivariate model. However, these covariates
239	were not significant (P > 0.05) in the adjusted vaccine effectiveness multivariate model. We kept
240	the sociodemographic variables (sex, age group, and nationality) in the adjusted model and
241	compared the change between unadjusted and adjusted models. The change in vaccine
242	effectiveness point estimates were <1% between unadjusted and adjusted model.
243	
244	4. Discussion
244 245 246	4. Discussion This retrospective cohort study was conducted between 24 December 2020 and 15 June
245	
245 246	This retrospective cohort study was conducted between 24 December 2020 and 15 June
245 246 247	This retrospective cohort study was conducted between 24 December 2020 and 15 June 2021 (i.e., 173 days) at a secondary hospital in Kuwait shows that full vaccination (i.e.,
245 246 247 248	This retrospective cohort study was conducted between 24 December 2020 and 15 June 2021 (i.e., 173 days) at a secondary hospital in Kuwait shows that full vaccination (i.e., immunization) via BNT162b2 is highly effective against symptomatic COVID-19 among this
<ul> <li>245</li> <li>246</li> <li>247</li> <li>248</li> <li>249</li> </ul>	This retrospective cohort study was conducted between 24 December 2020 and 15 June 2021 (i.e., 173 days) at a secondary hospital in Kuwait shows that full vaccination (i.e., immunization) via BNT162b2 is highly effective against symptomatic COVID-19 among this HCW population. Furthermore, ChAdOx1 one dose was relatively effective (Table 3).
<ul> <li>245</li> <li>246</li> <li>247</li> <li>248</li> <li>249</li> <li>250</li> </ul>	This retrospective cohort study was conducted between 24 December 2020 and 15 June 2021 (i.e., 173 days) at a secondary hospital in Kuwait shows that full vaccination (i.e., immunization) via BNT162b2 is highly effective against symptomatic COVID-19 among this HCW population. Furthermore, ChAdOx1 one dose was relatively effective (Table 3). Vaccine coverage with at least one dose among HCWs after 173 days (about 5.8 months)
<ul> <li>245</li> <li>246</li> <li>247</li> <li>248</li> <li>249</li> <li>250</li> <li>251</li> </ul>	This retrospective cohort study was conducted between 24 December 2020 and 15 June 2021 (i.e., 173 days) at a secondary hospital in Kuwait shows that full vaccination (i.e., immunization) via BNT162b2 is highly effective against symptomatic COVID-19 among this HCW population. Furthermore, ChAdOx1 one dose was relatively effective (Table 3). Vaccine coverage with at least one dose among HCWs after 173 days (about 5.8 months) was 82.1% of HCWs including 28.3% who received two doses. However, still there were 17.9%
<ul> <li>245</li> <li>246</li> <li>247</li> <li>248</li> <li>249</li> <li>250</li> <li>251</li> <li>252</li> </ul>	This retrospective cohort study was conducted between 24 December 2020 and 15 June 2021 (i.e., 173 days) at a secondary hospital in Kuwait shows that full vaccination (i.e., immunization) via BNT162b2 is highly effective against symptomatic COVID-19 among this HCW population. Furthermore, ChAdOx1 one dose was relatively effective (Table 3). Vaccine coverage with at least one dose among HCWs after 173 days (about 5.8 months) was 82.1% of HCWs including 28.3% who received two doses. However, still there were 17.9% of HCWs unvaccinated by the end of the study which is a concern. Healthcare workers have

of vaccine roll-out (i.e., 90% in UK; 79% in Israel; and 75% in USA) (Amit et al., 2021; Hall et
al., 2021; Thompson et al., 2021).

There were significant differences in vaccine coverage by demographics, occupation setting, and staff group. Similar differences by factors such as age, sex, ethnicity, and occupation have been reported in other studies (Curtis et al., 2021; Galanis, Vraka, Fragkou, Bilali, & Kaitelidou, 2020; Martin et al., 2021). The differences in vaccine coverage we reported among this population highlights the importance of equitable vaccination program to all HCWs in Kuwait.

264 Vaccine effectiveness of full vaccination with two doses of BNT162b2 vaccine was 265 94.5% (95% CI = 89.4%–97.2%) against symptomatic PCR-confirmed SARS-CoV-2 infection, 266 whereas it was 75.4% (95% CI = 67.2% - 81.6%) for ChAdOx1 single dose. These findings are 267 consistent with those from other population-level studies that estimated vaccine effectiveness 268 against SARS-CoV-2 infection (symptomatic and/or asymptomatic) among HCWs (Amit et al., 269 2021; Hall et al., 2021; Moustsen-Helms et al., 2021; Thompson et al., 2021) and those from 270 vaccine phase III trials (Knoll & Wonodi, 2021; Polack et al., 2020). For instance, in a study 271 from the US CDC, the authors reported that vaccine effectiveness against SARS-CoV-2 infection 272 among HCWs with full immunization ( $\geq$  14 days after BNT162b2 second dose) was 90% (95% 273 CI = 68% - 97%) (Thompson et al., 2021). In other studies on HCWs, BNT162b2 vaccine 274 effectiveness against SARS-CoV-2 infection ( $\geq$  7 day post second dose) was 85% (95% CI = 275 74% - 96%) in the UK (Hall et al., 2021), and it was 85% (95% CI = 71% - 92%) 15 - 24 days 276 after second dose in Israel (Amit et al., 2021). The main difference between these studies and 277 ours is that HCWs were regularly tested for SARS-CoV-2 infection (active surveillance) while in 278 our study it was based on reported of PCR-confirmed infection by HCWs to the hospital

279 management (passive surveillance). Nonetheless, it is mandatory for HCWs to report if they 280 were in close contact with a positive case or have tested positive via nasopharyngeal PCR. 281 Our findings highlight the effectiveness of vaccine in reducing the risk of symptomatic 282 infection among HCWs across sociodemographic factors (sex, age, and nationality) and across 283 occupation setting and staff group. Importantly, reducing infection rate among HCWs via 284 vaccination is critical to protect their health and lower the transmission risk to their contacts 285 (coworkers and patients) as well as to the public (Buitrago-Garcia et al., 2020). 286 The partial vaccination ( $\geq 28$  days after ChAdOx1 one dose) provided about 75% 287 protection. This similar with to the Phase III trial results (Hyams et al.; Knoll & Wonodi, 2021). 288 However, to best of our knowledge, there is no estimate on vaccine effectiveness of ChAdOx1 in 289 a HCW population. Furthermore, partial vaccination (≥14 days after first dose but before second 290 dose) also provided high level of protection from infection in HCWs in this study; however, this 291 limited by the relatively short at-risk person-time. Recent studies showed that partial vaccination 292 among HCWs in the U.S. ( $\geq$  21 days after BNT162b2 first dose) had vaccine effectiveness of 293 80% (95% CI = 59% – 90%) and 72% (95% CI = 58% – 86%) in a study from UK (Hall et al., 294 2021; Thompson et al., 2021). Both studies were based on regular SARS-CoV-2 testing program. 295 Moreover, a study from Israel reported 60% (95% CI = 38%-74%) one dose BNT162b2 vaccine 296 effectiveness against confirmed SARS-CoV-2 infection based on hospital records (passive 297 reporting) (Amit et al., 2021). It is worth mentioning that SARS-CoV-2 B.1.1.7 (Alpha) variant 298 was detected in Kuwait in January 2021 and could have been the dominant variant during the 299 study period; however, there are no available data in Kuwait to determine the percentage and 300 distribution of infections with this variant. Moreover, the B.1.617.2 (Delta) variant was reported

in Kuwait in late June 2021 (after the study ended); hence, it did not confound the effectivenessresults.

303 This study has several limitations. First, the study was based on one public secondary 304 hospital and might not be generalizable to HCWs in other public hospitals in Kuwait. However, 305 this hospital is one of the major healthcare facilities in Kuwait and serves over a quarter of the 306 country's population. Second, the identification of HCWs SARS-CoV-2 PCR-confirmed 307 infections was based on passive reporting to the hospital management due to lack of active 308 laboratory surveillance. However, it was/is required by all HCWs to report PCR-confirmed 309 infections to their upper management within each hospital's department. Furthermore, 310 underreporting PCR-confirmed infections might underestimate the 'actual' number of infections 311 regardless of vaccination status; if this disproportionately impacted those who were unvaccinated 312 compared to those who were vaccinated, this could overestimate vaccine effectiveness. Third, 313 vaccine effectiveness estimates for partial immunity ( $\geq$  14 days after BNT162b2 first dose 314 through receipt of second dose) had wide confidence intervals which likely due to the low 315 number of PCR-confirmed infections reported. 316 In conclusion, vaccine effectiveness of both BNT162b2 and ChAdOx1 COVID-19 317 vaccines in HCW under 'real-world' conditions demonstrated that vaccine is effective in 318 preventing most symptomatic infection across age groups, nationalities, occupation setting, and 319 staff groups. A significant proportion (17.9%) of HCWs were unvaccinated despite the vaccine 320 accessibility. Efforts are needed to better understand reasons for HCW vaccine hesitancy. 321 Although vaccination is highly effective against infection, hospitalization, and mortality as

322 shown in other studies, it is important for HCWs to continue to exercise physical distancing,

- 323 wear personal protective equipment while in contact with patients, and follow other infection
- 324 control and prevention measures.

### 325 **5. References**

326

- 327 Abu-Raddad, L. J., Chemaitelly, H., & Butt, A. A. (2021). Effectiveness of the BNT162b2 Covid-19
- 328 Vaccine against the B.1.1.7 and B.1.351 Variants. *New England Journal of Medicine*.
- 329 doi:10.1056/NEJMc2104974
- 330 Amit, S., Regev-Yochay, G., Afek, A., Kreiss, Y., & Leshem, E. (2021). Early rate reductions of
- 331 SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. *The Lancet,*
- 332 397(10277), 875-877. doi:10.1016/S0140-6736(21)00448-7
- Buitrago-Garcia, D., Egli-Gany, D., Counotte, M. J., Hossmann, S., Imeri, H., Ipekci, A. M., . . .
- 334 Low, N. (2020). Occurrence and transmission potential of asymptomatic and
- 335 presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis.

336 *PLOS Medicine, 17*(9), e1003346. doi:10.1371/journal.pmed.1003346

- 337 Curtis, H. J., Inglesby, P., Morton, C. E., MacKenna, B., Walker, A. J., Morley, J., . . . Goldacre, B.
- 338 (2021). Trends and clinical characteristics of COVID-19 vaccine recipients: a federated
- analysis of 57.9 million patients' primary care records in situ using OpenSAFELY.
- 340 *medRxiv*, 2021.2001.2025.21250356. doi:10.1101/2021.01.25.21250356
- Galanis, P. A., Vraka, I., Fragkou, D., Bilali, A., & Kaitelidou, D. (2020). Intention of health care
- 342 workers to accept COVID-19 vaccination and related factors: a systematic review and
- 343 meta-analysis. *medRxiv*, 2020.2012.2008.20246041. doi:10.1101/2020.12.08.20246041
- Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., . . . Alroy-Preis, S.
- 345 (2021). Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2
- 346 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide

347	vaccination campaign in Israel: an observational study using national surveillance data.
348	The Lancet, 397(10287), 1819-1829. doi:10.1016/S0140-6736(21)00947-8
349	Hall, V. J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., Heeney, J. L. (2021).
350	COVID-19 vaccine coverage in health-care workers in England and effectiveness of
351	BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort
352	study. <i>The Lancet, 397</i> (10286), 1725-1735. doi:10.1016/S0140-6736(21)00790-X
353	Hyams, C., Marlow, R., Maseko, Z., King, J., Ward, L., Fox, K., Finn, A. Effectiveness of
354	BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in
355	people aged at least 80 years: a test-negative, case-control study. The Lancet Infectious
356	Diseases. doi:10.1016/S1473-3099(21)00330-3
357	Knoll, M. D., & Wonodi, C. (2021). Oxford–AstraZeneca COVID-19 vaccine efficacy. The Lancet,
358	<i>397</i> (10269), 72-74. doi:10.1016/S0140-6736(20)32623-4
359	Martin, C. A., Marshall, C., Patel, P., Goss, C., Jenkins, D. R., Ellwood, C., Pareek, M. (2021).
360	Association of demographic and occupational factors with SARS-CoV-2 vaccine uptake in
361	a multi-ethnic UK healthcare workforce: a rapid real-world analysis. medRxiv,
362	2021.2002.2011.21251548. doi:10.1101/2021.02.11.21251548
363	Moustsen-Helms, I. R., Emborg, HD., Nielsen, J., Nielsen, K. F., Krause, T. G., Mølbak, K.,
364	Valentiner-Branth, P. (2021). Vaccine effectiveness after 1 <sup>st</sup> and
365	2 <sup>nd</sup> dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care
366	facility residents and healthcare workers – a Danish cohort study. <i>medRxiv</i> ,
367	2021.2003.2008.21252200. doi:10.1101/2021.03.08.21252200

368	Polack, F. P.	, Thomas, S. J.	, Kitchin, N	., Absalon, J.	, Gurtman, A	., Lockhart, S.,	Gruber	, W.	C.
200		,	,	., ,	, <b>o</b> ai cilian <i>i</i> , ,			,	•

- 369 (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England*
- 370 *Journal of Medicine*. doi:10.1056/NEJMoa2034577
- Thompson, M., Burgess, J., Naleway, A., Tyner, H., Yoon, S., Meece, J., . . . Gaglani, M. (2021).
- 372 Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19
- 373 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First
- 374 Responders, and Other Essential and Frontline Workers Eight U.S. Locations,
- 375 December 2020–March 2021. *MMWR. Morbidity and Mortality Weekly Report, 70*.
- 376 doi:10.15585/mmwr.mm7013e3
- 377 Vasileiou, E., Simpson, C. R., Robertson, C., Shi, T., Kerr, S., Agrawal, U., . . . Sheikh, A. (2021).
- 378 Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in
- 379 Scotland: National Prospective Cohort Study of 5.4 Million People. Available at
- 380 <u>http://dx.doi.org/10.2139/ssrn.3789264</u>.
- 381 Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., ...
- 382 Zuidewind, P. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222)
- 383 against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil,
- 384 South Africa, and the UK. *The Lancet, 397*(10269), 99-111. doi:10.1016/S0140-
- 385 6736(20)32661-1
- 386 Zhang, Z., Reinikainen, J., Adeleke, K. A., Pieterse, M. E., & Groothuis-Oudshoorn, C. G. M.
- 387 (2018). Time-varying covariates and coefficients in Cox regression models. *Annals of*
- 388 *translational medicine, 6*(7), 121-121. doi:10.21037/atm.2018.02.12
- 389

Characteristics		Total No.	Unvaccinated (row %)	Vaccinated with one dose only (ChAdOx1) (row %)	Vaccinated with one or tw doses (BNT162b2) <sup>a</sup> (row %)
	Female	2075	20.0	50.9	27.1
Sex	Male	1171	10.6	48.8	40.7
	P-value <sup>b</sup>		< 0.001	0.267	< 0.001
	20 - 30	443	28.2	30.9	40.9
	31 - 40	1518	19.7	55.0	25.3
Age groups	41 - 50	869	12.5	55.6	31.9
	> 50	416	11.3	41.6	47.1
	<i>P-value</i>		< 0.001	< 0.001	< 0.001
	Kuwaiti	575	20.7	18.6	60.7
Nationality	Non-Kuwaiti	2671	17.3	56.9	25.8
	P-value		0.054	< 0.001	< 0.001
	Offices and laboratory (lower risk)	446	23.3	36.8	39.9
	Patient facing non-clinical	170	15.3	47.1	37.7
	Outpatient	618	16.7	45.5	37.9
Occupation setting <sup>c</sup>	Inpatient wards and ambulance	1536	18.4	53.4	28.2
setting	Intensive Care (Higher risk)	407	11.6	58.2	30.2
	Other	69	24.6	66.7	8.7
	<i>P-value</i>		< 0.001	< 0.001	< 0.001
	Administrative or executive	54	31.5	24.1	44.4
	Nursing or health-care assistant	1985	17.4	59.5	23.1
	Doctor	541	11.5	30.1	58.4
Staff group	Specialist Staff	569	24.1	40.8	35.2
	Estates, porters, or security	15	0	100	0
	Pharmacist	82	22	29.3	48.8
	P-value		< 0.001	< 0.001	< 0.001
Fotal (%)		3246	581 (17.9)	1636 (50.4)	1029 (31.7)

Table 1: Characteristics of vaccinated and unvaccinated HCWs (n=3246) and factors associated with ChAdOx1 or BNT162b2 coverage at a major secondary
 hospital in Kuwait, December 24, 2020–June 15, 2021

- <sup>a</sup> Total vaccinated includes 108 HCWs who received one BNT162b2 vaccine dose and 921 who received two BNT162b2 vaccine doses
- 394
- <sup>395</sup> <sup>b</sup> P-values (comparing the column percentages of vaccinate status by sociodemographic, occupation setting, and staff group categories were calculated using
- 396 Pearson's chi-square test (cells with  $\geq$ 5 observations) or Fisher's exact test (cells with <5 observations) in STATA statistical software.
- <sup>c</sup> Occupation setting categories were: 1: office or laboratory; 2: Hospital pharmacy, 3: outpatient including radiology, day ward, general practice, or renal dialysis
- 398 unit; 4: inpatient ward, theatres, emergency department, maternity unit or labor ward, or ambulance; 5: intensive care; and 6: other (e.g., plaster and observational
- 399 rooms).
- 400

401	Table 2: Prevalence of SARS-CoV-2 PCR-confirmed infections in HCWs (n=3246) received BNT162b2 or ChAdOx1 COVID-19 vaccines at a major secondary
402	hospital in Kuwait, December 24, 2020–June 15, 2021

Characteristics	Categories	No. Unvaccinated (Infection %)	Vaccinated with one dose only (ChAdOx1) n (Infection %)	Vaccinated with one or two doses (BNT162b2) n (Infection %) <sup>a</sup>	P-value <sup>b</sup>	
	Female	456	1057	562	< 0.001	
Sex		(20.8)	(7.1)	(2.0)		
Sex	Male	124	571	476	< 0.001	
	Wate	(15.3)	(4.9)	(1.9)	<0.001	
	20 - 30	125	137	181	< 0.001	
	20 30	(21.6)	(9.5)	(2.8)	<0.001	
	31 - 40	299	835	384	< 0.001	
Age groups	51 - 40	(16.7)	(6.6)	(0.8)	<0.001	
Age groups	41 - 50	109	483	277	< 0.001	
	41 - 50	(25.7)	(6.0)	(2.2)	<0.001	
	> 50	47	173	196	< 0.001	
	- 50	(19.2)	(3.5)	(3.1)		
	Kuwaiti	119	107	349	< 0.001	
Nationality	Kuwalu	(16.8)	(7.5)	(2.0)	<0.001	
Ivationality	Non-Kuwaiti	461	1521	689	< 0.001	
		(20.4)	(6.3)	(1.9)	<0.001	
	Offices and laboratory (lower risk)	104	164	178	< 0.001	
	Offices and faboratory (lower fisk)	(26.9)	(9.2)	(2.8)	<0.001	
	Patient facing non-clinical	26	80	64	< 0.001	
	Patient facing non-crimical	(19.2)	(5.0)	(3.1)	<0.001	
Occupation	Outpatient	103	281	234	< 0.001	
setting <sup>c</sup>		(12.6)	(3.2)	(2.1)	<0.001	
	Inpatient wards and ambulance	283	820	433	< 0.001	
		(19.8)	(6.5)	(0.9)	<0.001	
	Intensive Care (Higher risk)	47	237	123	< 0.001	
		(21.3)	(7.2)	(3.3)	<0.001	

	Other	17	46	6	0.508
		(11.8)	(10.9)	0.0	0.508
	Administrative or executive	17	13	24	< 0.001
	Administrative of executive	(23.5)	(15.4)	(4.2)	<0.001
	Nursing or health-care assistant	346	1181	458	< 0.001
		(20.5)	(6.4)	(1.3)	<0.001
	Doctor	62	163	316	<0.001
Staff group		(19.4)	(5.5)	(1.9)	
Starr group	Specialist Staff	137	232	200	<0.001
		(19.0)	(6.5)	(2.5)	
	Estates, porters, or security	0	15	0	
		0.0	0.0	0.0	-
	Pharmacist	18	24	40	0.866
		(5.6)	(8.3)	(6.1)	

403

404 <sup>a</sup> Total vaccinated includes 108 HCWs who received one BNT162b2 vaccine dose and 921 who received two BNT162b2 vaccine doses

405 <sup>b</sup> P-values (comparing the row percentages of vaccinate status by sociodemographic, occupation setting, and staff group categories were calculated using

406 Pearson's chi-square test (cells with  $\geq$ 5 observations) or Fisher's exact test (cells with <5 observations) in STATA statistical software. "-" because of lack of

407 enough data for chi-square statistic to test relationship.

408 ° Occupation setting categories were: 1: office or laboratory; 2: Hospital pharmacy, 3: outpatient including radiology, day ward, general practice, or renal dialysis

409 unit; 4: inpatient ward, theatres, emergency department, maternity unit or labor ward, or ambulance; 5: intensive care; and 6: other.

## 411 **Table 3**. Effectiveness of ChAdOx1 and BNT162b2 COVID-19 vaccines against SARS-CoV-2 symptomatic infection among HCWs (n= 3246) at a major

COVID-19 vaccination status	Total person time (days)	Number of PCR positives	Incidence rate per 100,000 person-days	Unadjusted vaccine effectiveness % (95% CI) <sup>a</sup>	Adjusted vaccine effectiveness % (95% CI) <sup>a, b</sup>
Unvaccinated	90,367	114	126.2	Reference	Reference
Partially vaccinated					
$\geq$ 28 days after receiving ChAdOx1 first dose only <sup>c</sup>	159,423	87	54.6	75.5 (67.6 - 81.5)	75.4 (67.2 - 81.6)
≥ 14 days after receiving BNT162b2 first dose through receipt of second dose	7,196	2	27.8	91.6 (65.9 - 97.9)	91.4 (65.1 - 97.9)
Fully vaccinated					
≥ 7 days after BNT162b2 second dose	90,015	12	13.3	95.1 (90.6 - 97.4)	94.5 (89.4 - 97.2)

412 secondary hospital in Kuwait, December 24, 2020–June 15, 2021

413

414 <sup>a</sup> Vaccine effectiveness was estimated using a Cox proportional hazards model accounting for time-varying immunization status in STATA statistical software.

415 <sup>b</sup>Hazard ratio is adjusted for age, sex, and nationality

416 <sup>c</sup> Participants received first dose of ChAdOx1 but had not received second dose by the end of the study period.